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Background: Secretory phospholipase A2 (sPLA2) is a family of pro-atherogenic enzymes involved in lipoprotein remodeling and activation of 
inflammatory pathways. In acute coronary syndrome (ACS), high sPLA2-IIA levels predict major cardiovascular events (MACE).
Methods: Randomized, double-blind, prospective controlled clinical trial (Phase 2B) designed to investigate effects of sPLA2 inhibition with 
varespladib 500 mg (A-002) daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on LDL cholesterol (LDL-C), C-reactive protein 
(CRP), sPLA2 and MACE (unstable angina [UA], myocardial infarction [MI], stroke, revascularization, death) and safety. 625 ACS subjects were 
randomized within 96 h of index event, and treated for 16 weeks to investigate changes in biomarkers and 24 weeks to evaluate changes in clinical 
events and safety.
Results: Compared to placebo, varespladib reduced levels of LDL-C by 6% (p<0.02) at the time of the primary endpoint and at 16 weeks, hs-CRP 
by 26% (p<0.01) and sPLA2-IIA by 70% (p<0.001) (Figure). Favorable trends were noted for UA/MI; however total MACE events were not different 
(varespladib 23 and placebo 24). Elevated serum transaminases were observed in 3 varespladib-treated subjects (1.0%) and 2 placebo-treated 
subjects (0.6%).
Conclusions: Varespladib reduced LDL-C and inflammatory biomarkers in ACS patients treated with conventional therapy including atorvastatin 80 
mg daily. Based on these data, a 6500 subject Phase III trial is planned.
